Pricing Log in Create free account

Aclaris Therapeutics, Inc. (ACRS) vs Bright Minds Biosciences Inc. (DRUG)

Aclaris Therapeutics, Inc. and Bright Minds Biosciences Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and Bright Minds Biosciences Inc. are of similar size ($534.7M and $513.7M). Bright Minds Biosciences Inc. has the higher net margin (0.00% vs −921.5%) and the higher return on invested capital (0.00% vs −163.4%). Across the 13 metrics below, Bright Minds Biosciences Inc. leads on 10 and Aclaris Therapeutics, Inc. on 3.

Valuation

Metric ACRS DRUG Biotechnology median
P/E n/m n/m 8.50
P/S 56.96 n/m 9.71
P/B 3.76 2.27 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 47.13 n/m 9.21
Earnings yield (17.68%) (4.05%) (33.15%)
Free cash flow yield (13.28%) (3.52%) (25.50%)

Profitability

Metric ACRS DRUG Biotechnology median
Gross margin 12.90% 0.00% 65.16%
Operating margin (1,050.16%) 0.00% 0.00%
Net margin (921.50%) 0.00% 0.00%
Free cash flow margin (756.50%) 0.00% 0.00%
Return on equity (59.10%) (13.64%) (56.36%)
Return on assets (41.07%) (13.52%) (48.04%)
Return on invested capital (163.35%) 0.00% 0.00%

Growth

Metric ACRS DRUG Biotechnology median
Revenue growth (TTM) (51.04%) — 6.02%
EPS growth (last fiscal year) 69.01% (164.58%) 30.26%
Revenue growth, 5-year CAGR 3.84% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRS DRUG Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.46 121.98 4.72
Net debt to EBITDA 1.20 5.98 0.96

Dividend

Metric ACRS DRUG Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACRS DRUG Biotechnology median
Market cap 513.72m 534.73m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack